Pancreatic α-cells express voltage-gated Na+ channels (NaChs) which support the generation of electrical activity leading to increase in intracellular calcium and causes exocytosis of glucagon. Ranolazine, a NaCh blocker, is approved for treatment for angina. In addition to its anti-anginal effects, ranolazine has been shown to reduce HbA1c in patients with type 2 diabetes (T2DM) and coronary artery disease; however, the mechanism behind its anti-diabetic effect has been unclear. We tested the hypothesis that ranolazine exerts its anti-diabetic effects by inhibiting glucagon release via blockade of NaChs in the pancreatic α-cells. Our data show that ranolazine, via blockade of NaChs in pancreatic α-cells, inhibits their electrical activity and reduces glucagon release. We found that glucagon release in human pancreatic islets is mediated by the Nav1.3 isoform. In animal models of diabetes ranolazine and a more selective NaCh blocker (GS-458967) lowered postprandial and basal glucagon levels, which were associated with a reduction in hyperglycemia, confirming that glucose-lowering effects of ranolazine are due to blockade of NaChs. This mechanism of action is unique in that no other approved anti-diabetic drugs act via this mechanism, and raises the prospect that selective Nav1.3 blockers may constitute a novel approach for the treatment of diabetes.
* These authors contributed equally
- Received October 10, 2013.
- Accepted April 30, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.